Biochemist Catalyzes Multidisciplinary Biomaterials Research

It's odd to find a biochemist holding a high-ranking management position in the materials sciences division of a major national laboratory. And the team that Mark Alper has assembled at Lawrence Berkeley Laboratory in Berkeley, Calif.--consisting of organic chemists, enzymologists, chemical engineers, and even a journal editor--may seem even stranger. But in the four years since Alper founded the Enzymatic Synthesis of Materials Program at the Berkeley lab, this eclectic collection of investiga

Written byLaurel Joyce
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Alper's team is one of only a few groups in the United States focusing on the blending of biotechnology and materials research. They are at the forefront of a very exciting, very promising field--bioderived materials--that can have a variety of applications, including artificial skin, optics, paper production, synthetic spider silk, and custom-made polymers.

"After people started asking me, `What's a biochemist doing in a materials division?' I had to come up with some justification," quips Alper. "I figured I'd create a major program so people wouldn't ask me anymore."

The mission of Alper's team is to take on a novel challenge: using biological processes to make materials. The group's seven principal scientists are already coaxing enzymes, the super-efficient facilitators of natural reactions, to do their bidding. Creating commercially viable materials through biological processes is by no means unprecedented. In fermentation, for ex- ample, a biological process creates something new--such as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies